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A B S T R A C T
Alzheimer's disease (AD) is the most common form of dementia. Mutations in the gene PSEN1 encoding Presenilin1 are known to cause familial forms of AD with
early age of onset. The most common mutation in the PSEN1 gene is the E280A mutation. iPSCs are an optimal choice for modeling AD, as they can be differentiated
in vitro into neural cells. Here, we report the generation of two isogenic iPSC lines with either a homozygous or a heterozygous E280A mutation in the PSEN1 gene.
The mutation was introduced into an iPSC line from a healthy individual using the CRISPR-Cas9 technology.
Resource table
Unique stem cell lines identifier 1. BIONi010-C+ homozygous E280A=BIONi010-C-29
2. BIONi010-C+ heterozygous E280A=BIONi010-C-30
Alternative names of stem cell lines 1. BIONi010-C E280 +/+ (homozygous line)
2. BIONi010-C E280 +/− (heterozygous line)
Institution Bioneer A/S Hørsholm Denmark and University of Copenhagen (UCPH) Copenhagen Denmark
Contact information of distributor Contact at Bioneer: Benjamin Schmid,bsc@bioneer.dk– Contact at UCPH: Kristine Freude,kkf@sund.ku.dk




Method of reprogramming Episomal plasmids (Okita et al., 2011)
Multiline rationale Mutated isogenic clones
Gene modification YES
Type of modification Induced point mutation
Associated disease Alzheimer's disease (AD)
Gene/locus PSEN1/Chr14:73664808
Method of modification CRISPR-Cas9
Name of transgene or resistance N/A
Inducible/constitutive system N/A
Date archived/stock date September 2017
Cell line repository/bank 1. BIONi010-C-29:https://hpscreg.eu/cell-line/BIONi010-C-29
2. BIONi010-C-30:https://hpscreg.eu/cell-line/BIONi010-C-30
Ethical approval The study was approved by the Ethics Committee of the Capital Region of Denmark (H-4-2011-157), and written informed consent was obtained
from the participant before enrolment
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The exact mechanisms leading to Alzheimer's disease (AD) remain
still unknown. In order to better understand disease development and
underlying cellular pathological mechanisms, we have established two
isogenic iPSC lines containing either a heterozygous or a homozygous
E280A mutation in the PSEN1 gene, which are known to result in AD.
Resource details
The mutation E280A in the PSEN1 is one of the most common
mutations related to familial forms of Alzheimer's disease (AD). Ample
patient based information is available based on studies from a large
kindred from the Colombian state of Antioquia. (Sepulveda-Falla et al.,
2012). This specific mutation is therefore highly relevant for estab-
lishment of an iPSC based disease model, as the cell model is sub-
stantially supported by patient phenotype information, which will fa-
cilitate validation of the in vitro model.
For this study, the E280A mutation was inserted into the human
iPSC line BIONi010-C, which had earlier been established from a skin
biopsy obtained from a healthy male individual aged 18 (Rasmussen
et al., 2014).
The point mutation resulting in an amino acid change from glutamic
acid (E) to alanine (A) was knocked into the PSEN1 gene by using the
CRISPR-Cas9 system (Jinek et al., 2012). The nucleotide substitution
was confirmed by restriction digest (data not shown) followed by DNA
sequencing. Sequencing analysis confirmed a successful A > C transi-
tion causing the E280A mutation on protein level in both a hetero-
zygous and homozygous manner. The two lines are further referred to
as BIONi010-C-E280A +/− and BIONi010-C-E280A +/+, respec-
tively (Fig. 1A, Table 1).
Pluripotency of the gene-edited lines was confirmed by im-
munocytochemistry (ICC) and quantified by flow analysis. Both cell
lines show clear expression of OCT4, NANOG, SSEA4, SSEA3, TRA-1-60
and TRA-1-81 (Fig. 1B). The differentiation potential of the iPSCs was
confirmed via spontaneous differentiation into endo- and mesodermal
cell types (Fig. 1D). Cells were differentiated to neural progenitor cells
and stained for PAX6 and Nestin (Fig. 1D) the cells hereby showed
capability of ectodermal differentiation. A karyotype analysis was car-
ried out to confirm chromosomal integrity. The results showed a normal
46, XY karyotype without detectable abnormalities (Supplementary
Fig. 1A). Investigation of cells by light microscopy confirmed a normal
iPSC morphology throughout the gene editing process (Fig. 1C). Finally,
an STR analysis was performed to confirm cell line identity (Available




Cells were grown on Matrigel coated plates in E8 media and in-
cubated at 37 °C and 5% CO2. At 80% confluency, cells were detached
by treating cells with Accutase for 5min after which 0.8× 106 cells
were nucleofected. Nucleofection was made by using the Lonza nu-
cleofector, P3 solution and the CA167 pulse setting. Nucleofected cells
were transferred to Matrigel coated plates and single colonies were
picked manually for analysis after 7 days.
Editing was performed using the CRISPR-Cas9 system in combina-
tion with an ssODN (single stranded oligo deoxynucleotide) as homo-
logous template containing the E280A mutation. Two silent mutations
(changing the DNA sequence but not the protein sequence) were in-
serted to avoid repeated cutting by the CRISPR-Cas9 and to add a re-
striction enzyme recognition site for Bsa1. The 20 nt crRNA was de-
signed with the software http://crispr.mit.edu/. crRNA, tracrRNA,
ssODN, and Cas9 protein were all ordered from Integrated DNA
Technologies (IDT).
Genotyping and restriction enzyme
To screen for positive clones, DNA was extracted using the prepGEM
kit (ZyGEM) followed by PCR using the AmpliTaq GOLD DNA poly-
merase (Thermo Fisher) according to the manufacturer's instructions.
40 cycles consisting of 30 s of denaturation at 94 °C, 30 s of annealing at
60 °C and 60 s of elongation at 72 °C was performed in a T100 ther-
mocycler from Bio-Rad. The primers SURV PSEN1 FW/RV (IDT) used
Fig. 1. A) Sequencing analysis of the PSEN1 gene revealed a heterozygous and a homozygous insertion of the pathogenic E280A mutation depicted by the arrow in
the middle of the sequencing analysis. In addition, two silent mutations were inserted to block the CRISPR cutting site (two arrows at the left side). B) Left:
Immunofluorescence microscope analysis of the stem cell markers OCT4, SSEA4, NANOG, TRA-1-81, TRA-1-60 and SSEA3. Right: Flow cytometry analysis of the stem
cell markers OCT4, SOX2, SSEA4, and TRA-1-81 quantified on unstained cells. SSEA1 was used as marker for differentiated cells. C) Bright-field image of the two
gene-edited iPS cell lines. E) Immunofluorescence microscope analysis of endo-, meso-, and ectodermal cell types with the respective markers AFP, SMA and PAX6.
Cells were stained with the pluripotency marker OCT4 as a negative control.
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for PCR, were designed to cover the mutation at locus Chr14:73664808
and produces a 400 bp product (Table 3). The screening was carried out
by restriction digest using Bsa1 for 1 h at 37 °C (New England Biolabs).
Sequencing
Positive clones were sequenced by Sanger sequencing using primer
SURV PSEN1 seq (Table 3).
Karyotyping and quality control
Quality control was performed after the lines had been banked and
are listed in Table 2. The general morphology of the cells was in-
vestigated daily by light microscopy. When cells were 70–85% con-
fluent, karyotyping was initiated by treating cells with Colcemid
(Gibco) for 1.5 h after which they were detached with Accutase for
5min. Next, cells were incubated with 0.075M KCl for 30min at 370C
and afterwards fixed with a mixture of 25% acidic acid and 75% me-
thanol. Fixed cells were placed at -20 °C overnight and then shipped for
G-band karyotyping at the Institute of Medical Genetics and Applied
Genomics, University of Tuebingen. For each cell line 15 metaphases
where analysed. BIONi010-C E280A +/− was sent for karyotyping at
passage 35 and BIONi010-C E280A +/+ at passage 38. STR analysis
was performed by extracting DNA (Qiagen) and subsequently analyzing
the DNA using the AmpFLSTR Identifier PCR Amplification kit ac-
cording to manufacturer's instructions (Applied Biosystems). Cells were
tested for microbiological contamination by growing 500 μL of the su-
pernatant in LB medium for 2 days at 370C and tested for mycoplasma
using the PCR mycoplasma test kit (PromoKine).
Immunocytochemistry
Expression of pluripotency markers was investigated using a Leica
DMRB-fluorescence microscope (Leica Microsystems Wetzlar,
Germany). Cells were fixed in 4% PFA for 20min at RT and labeled
according to standard ICC procedures by permeabilizing fixed cells with
2% Triton X-100 in PBS for 20min at RT followed by 30min of blocking
with 3% BSA. All antibodies were diluted in 3% BSA (OCT4, NANOG,
SSEA4, SSEA3, Tra-1-60 and Tra-1-81) and incubated overnight at 4 °C.
The primary antibodies (Table 3) were visualized with Alexa488 or
Alexa647 as secondary antibodies diluted 1:200 (Life Technologies).
Secondary antibodies were incubated in darkness for one hour at RT
and and all samples were stained with Hoechst bisbenzimide 33,258.
Differentiation potential
For analysis of differentiation potential, embryoid bodies were
formed for 7 days in E8 media after which, cells were spontaneously
differentiated in fibroblast media for 14 days on Matrigel coated plates.
Cells were afterwards immunocytochemically stained for smooth muscle
actin (mesoderm), alpha feto protein (endoderm). Fluorescent images
showing the expression of the two markers were acquired on a Leica
DMRB-fluorescence microscope. iPSCs were also differentiated into
neural progenitor cells (ectoderm), by forming embryoid bodies for
7 days in neural induction media and plating the embryoid bodies on
Matrigel coated plates for another 7 days in neural induction media.
Neural induction media consisted of Neurobasal media (Thermo Fisher),
DMEM-F12 (Gibco), B-27 (Thermo Fisher), N-2 (Thermo Fisher),
SB431542 (SMS), LDN193189 (Sigma), Glutamax (Thermo Fisher), Pen/
Strep (Sigma). Cells were immunocytochemically stained for PAX6 and
Nestin and images acquired on a Leica DMRB-fluorescence microscope.
Flow cytometry
Flow cytometry was used to quantify pluripotency markers ex-
pressed by the cell lines using the Staining Buffer Set from Invitrogen.
Cells were detached with Accutase for 5–10min and 0.2×105 cells
were fixed in 0.5 mL of the fixation/permeabilizationbuffer according
to the guidelines. After 30min incubation at RT, the cells were washed
three times with permeabilization buffer and then incubated for 45min
with 100 μL of the diluted antibody. Cells were washed additionally
three times and afterwards run at a calibrated BD Accuri C6 flow cyt-
ometer (analyze 50.000 cells at high speed in 150 µL buffer). The
analysis was done using the FlowJo software.
Table 1
Summary of lines.
iPSC line names Abbreviation in figures Gender Age Ethnicity Genotype of locus Disease
BIONi010-C-29 BIONi010-C E280A +/+ Male 18 African CC N/A
BIONi010-C-30 BIONi010-C E280A +/− Male 18 African AC N/A
Table 2
Characterization and validation.
Classification Test Result Data
Morphology Photography Visual record of the lines: normal Fig. 1panel C
Phenotype Qualitative analysis by
immunocytochemistry
Positive for OCT4, NANOG, SSEA4, SSEA3, Tra-1-60 and Tra-1-81 Fig. 1panel B
Quantitative analysis by flow cytometry BIONi010-C-E280A +/− positive for: Oct3/4:95.8%Sox2:98.3%
SSEA4:98.8%Tra181:73,5%
SSEA1(control):0.7%




Genotype Karyotype (G-banding), All 46, XY, Resolution 300–400 bp Supplementary Fig. 1 panel A
Identity STR analysis DNA profiling performed Available with the authors
16 sites tested, all match
Mutation analysis Sequencing Successful integration of both heterozygous and homozygous mutation A > C. Fig. 1panel A
Microbiology and virology Mycoplasma Mycoplasma testing by PCR Mycoplasma Test Kit was negative Supplementary Fig. 1 panel B
Differentiation potential Spontaneous differentiation Positive for: AFP and SMA. Negative for OCT4. Positive for PAX6 and Nestin
after 10 days of neural induction
Fig. 1panel D
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Table 3
Reagents details.
Antibodies used for immunocytochemistry/flow-cytometry
Antibody Dilution Company Cat # and RRID
Pluripotency Marker Goat anti-OCT4 1:200 Santa Cruz Cat: sc-8628 RRID:AB_653551
Pluripotency Marker NANOG 1:50 Peprotech Cat: 500-P236 RRID:AB_1268805
Pluripotency Marker Rat anti-SSEA3 1:100 Biolegend Cat: 330302 RRID: AB_1236554
Pluripotency Marker Mouse anti-SSEA4 1:100 Biolegend Cat: 330402 RRID: AB_1089208
Pluripotency Marker Mouse anti-TRA-1-60 1.200 Biolegend Cat: 330602 RRID: AB_1186144
Pluripotency Marker Mouse anti-TRA-1-81 1:200 Biolegend Cat: 330702 RRID: AB_1089240
Pluripotency Marker OCT4 PE 1:25 BD Pharmigen Cat: 560186 RRID:AB_1645331
Pluripotency Marker SOX2 AF647 1:50 BD Pharmigen Cat: 560294 RRID:AB_1645324
Pluripotency Marker TRA-1-81 AF647 1:25 BD Pharmigen Cat: 500793 RRID:AB_1645449
Pluripotency Marker SSEA4 PE 1:25 BD Pharmigen Cat: 560128 RRID:AB_1645533
Differentiation Markers SSEA1 PE 1:25 BD Pharmigen Cat: 560142 RRID:AB_1645246
Differentiation Markers Rabbit anti-Alpha-1-Fetoprotein 1:200 DAKO Cat: A0008 RRID:AB_2650473
Differentiation Markers Mouse anti-Smooth Muscle Actin 1:200 DAKO Cat: M0851 RRID:AB_2313736
Differentiation Markers Rabbit anti-PAX6 1:100 Convanca Cat# PRB-278P RRID: AB_2565003
Differentiation Markers Mouse anti-Nestin 1:1000 Millipore Cat# MAB5326 RRID: AB_11211837
Secondary antibodies Donkey Anti-Mouse IgG Alexa fluor 488 1:200 Life technologies Cat#A21202 RRID: AB_141607
Secondary antibodies Donkey Anti-Mouse IgG Alexa fluor 647 1:200 Invitrogen Cat# A31571 RRID: AB_162542
Secondary antibodies Donkey Anti-Rat IgG Alexa fluor 594 1:200 Invitrogen Cat# A21209 RRID: AB_2535795
Secondary antibodies Donkey Anti-Goat IgG Alexa fluor 488 1:200 Invitrogen Cat# A11055 RRID: AB_2534102
Secondary antibodies Donkey Anti-Rabbit IgG Alexa fluor 488 1:200 Life technologies Cat# A21206 RRID: AB_2535792
sgRNA, ssODN and primers




SURV PSEN1 FW/RV (PCR mutation analysis) PSEN1 CCACCAGTTCACCTGCCATTT/AAGAGATCTGCAGGAGTTCCA
SURV PSEN1 seq (Sequencing) PSEN1 CACCCATTTACAAGTTTAGC
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